National and Kapodistrian University of Athens
Η μητρική ακτιβίνη Α ορού ως βιολογικός δείκτης στη διάγνωση της προεκλαμψίας, της ενδομήτριας υπολειπόμενης ανάπτυξης του εμβρύου και του συνδρόμου Down
Abstract
dc:descriptionOBJECTIVE: To determine whether the behaviour of the maternal serum activin A in preeclamptic and IUGR pregnancies where a “poor” placentation takes place and in the Down’s syndrome, where functional disorder of the placenta (and not a failure in its microarchitecture) exists, could nominate activin A as a new biological marker in the diagnosis of these conditions. MATERIAL: We recruited patients of the High Risk Pregnancy Unit of the ‘A Academic Department of Obstetrics and Gynecology at the “Alexandra Maternity Hospital”. They were included patients with preeclampsia, patients carrying an IUGR fetus, and patients with a Down syndrome baby. As control group we recruited pregnant women with an uncomplicated pregnancy. All women had a singleton pregnancy between 20 and 37 weeks. The preeclampsia group included women with a history of arterial blood pressure >140/95mmHg, sustained proteinuria >300mg/24h, with or without oedemas or other symptoms. The IUGR group included women with a fetal growth below the 10th centile for age and sex in conjunction with a head circumference to abdominal circumference ratio higher than 1. The Down syndromes’ group included women with diagnosed trisomy 21 who had undergone an amniocentesis due to high risk of the abnormality. METHODS: A dedicated history sheet was filled in by the patients and blood sample was taken from them. The sample was centrifuged at 3500 X g for 15 minutes and the serum stored at -800C until assayed. The assay used the “sandwich” ELISA technique and the values were expressed in ng/ml. After the proper rearrangements the final group consisted of 74 patients (39 with preeclampsia, 31 with IUGR and 4 with Down syndrome) and 24 healthy pregnant women. A statistical analysis of the results was conducted thereafter. Differences were considered significant when p<0.05. RESULTS: The mean value of the activin A in maternal serum of the preeclamptic women [24.3654ng/ml (95% CI 11.3087-37.4220)] and in the serum of the IUGR patients [10.8565ng/ml (95% CI 2.7939-18.9190)] was significantly higher than the mean value in the serum of the healthy pregnants [2.369ng/ml (95% CI 1.579-3.159)]. The difference found to be statistically significant (p<0.05). Regarding the Down syndrome group such a conclusion could not be extracted due to the small power of the sample in this category. In this group though the mean value of the activin A (1.2750ng/ml) was comparable with that of the control group. CONCLUSIONS: Activin A rises in the maternal serum of the preeclamptic and IUGR patients significantly and this behaviour is considered so important that can nominate activin A as a novel diagnostic biological marker in the management of these disorders, where nowadays equivocal biochemical tests only exist. In Down syndrome no such conclusions could be extracted.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katsoulis, Ioannis
- Κατσούλης, Ιωάννης
Subjects
dc:subject × 14- Μητρική ακτιβίνη Α
- Προεκλαμψία
- Ενδομήτρια υπολειπόμενη ανάπτυξη εμβρύου
- Σύνδρομο Down
- Maternal serum activin A
- Preeclampsia
- Intrauterine growth restriction of the fetus
- Down’s syndrome
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41792